Your browser is no longer supported. Please, upgrade your browser.
ACOR Acorda Therapeutics, Inc. daily Stock Chart
ACOR [NASD]
Acorda Therapeutics, Inc.
Index- P/E- EPS (ttm)-4.67 Insider Own1.50% Shs Outstand47.71M Perf Week24.87%
Market Cap41.91M Forward P/E- EPS next Y-1.84 Insider Trans0.00% Shs Float47.16M Perf Month76.70%
Income-221.80M PEG- EPS next Q-0.31 Inst Own61.10% Short Float26.73% Perf Quarter12.09%
Sales159.90M P/S0.26 EPS this Y4.70% Inst Trans0.14% Short Ratio2.23 Perf Half Y-20.47%
Book/sh6.10 P/B0.14 EPS next Y-12.20% ROA-28.10% Target Price- Perf Year-58.25%
Cash/sh1.32 P/C0.63 EPS next 5Y29.00% ROE-74.60% 52W Range0.42 - 2.82 Perf YTD-59.06%
Dividend- P/FCF- EPS past 5Y16.45% ROI-48.20% 52W High-70.33% Beta1.32
Dividend %- Quick Ratio0.90 Sales past 5Y-13.70% Gross Margin83.00% 52W Low97.70% ATR0.14
Employees344 Current Ratio1.10 Sales Q/Q-32.90% Oper. Margin- RSI (14)62.75 Volatility26.48% 19.41%
OptionableYes Debt/Eq0.77 EPS Q/Q36.90% Profit Margin- Rel Volume0.61 Prev Close0.87
ShortableYes LT Debt/Eq0.54 EarningsAug 04 AMC Payout- Avg Volume5.66M Price0.84
Recom3.00 SMA2023.21% SMA5040.18% SMA200-15.33% Volume3,459,055 Change-4.29%
Aug-14-19Downgrade H.C. Wainwright Buy → Neutral $31 → $6
May-23-19Initiated Wedbush Neutral
Dec-11-18Downgrade Goldman Neutral → Sell
Aug-07-18Reiterated Stifel Hold $15 → $25
Feb-16-18Upgrade Piper Jaffray Neutral → Overweight
Jan-17-18Reiterated H.C. Wainwright Buy $34 → $31
Nov-28-17Resumed Piper Jaffray Neutral $22
Nov-16-17Downgrade Stifel Buy → Hold $26 → $15
Nov-16-17Downgrade Raymond James Mkt Perform → Underperform
Nov-09-17Initiated Oppenheimer Perform
Nov-08-17Initiated H.C. Wainwright Buy $35
Oct-06-17Resumed Goldman Sell $20
Jul-11-17Initiated Jefferies Hold
Apr-03-17Downgrade JP Morgan Overweight → Neutral
Feb-15-17Upgrade Goldman Sell → Neutral
Nov-30-16Upgrade JP Morgan Neutral → Overweight
Oct-04-16Resumed Leerink Partners Mkt Perform $25
Mar-30-16Initiated Goldman Sell
Sep-01-15Initiated Raymond James Mkt Perform
Jun-09-15Initiated Guggenheim Neutral
Oct-20-20 11:17AM  
09:47AM  
Sep-29-20 11:25AM  
Sep-17-20 07:00AM  
Aug-04-20 06:15PM  
04:20PM  
04:00PM  
Jul-31-20 12:45PM  
Jul-28-20 07:00AM  
Jul-08-20 06:40PM  
Jun-16-20 04:46PM  
07:30AM  
Jun-12-20 09:36AM  
Jun-09-20 10:01AM  
Jun-04-20 11:31AM  
Jun-03-20 09:05AM  
May-06-20 07:23PM  
01:27PM  
May-05-20 06:15PM  
04:00PM  
Apr-28-20 07:00AM  
Apr-24-20 11:49AM  
Apr-16-20 05:45PM  
Apr-07-20 05:50PM  
12:37PM  
11:14AM  
Apr-03-20 08:31AM  
Apr-02-20 10:08AM  
Mar-30-20 08:06AM  
Mar-17-20 12:00PM  
Mar-14-20 11:30AM  
Feb-24-20 07:00AM  
Feb-18-20 01:44AM  
Feb-14-20 11:57AM  
Feb-13-20 10:25AM  
09:15AM  
07:00AM  
Feb-10-20 10:20AM  
Feb-06-20 12:31PM  
05:51AM  
Jan-30-20 07:00AM  
Jan-24-20 08:54AM  
Jan-15-20 07:00AM  
Jan-08-20 07:00AM  
Jan-07-20 10:55AM  
Jan-03-20 07:55AM  
Dec-26-19 07:00AM  
Dec-23-19 05:30AM  
Dec-12-19 10:31AM  
Dec-04-19 11:30AM  
Dec-02-19 10:22AM  
Nov-27-19 07:00AM  
07:00AM  
Nov-12-19 07:00AM  
Nov-08-19 10:21AM  
Nov-07-19 11:08AM  
11:05AM  
11:04AM  
08:50AM  
Nov-06-19 04:40PM  
04:28PM  
10:56AM  
10:34AM  
Nov-05-19 11:45AM  
11:09AM  
Nov-04-19 05:25PM  
04:00PM  
11:18AM  
Nov-01-19 02:49PM  
12:07PM  
Oct-31-19 12:40PM  
12:33PM  
11:54AM  
09:26AM  
Oct-28-19 10:32AM  
Oct-25-19 07:12AM  
Oct-24-19 11:24AM  
07:36AM  
Oct-23-19 04:00PM  
Oct-22-19 07:00AM  
Oct-21-19 07:00AM  
Oct-07-19 10:00AM  
Oct-03-19 09:00AM  
Sep-26-19 08:40AM  
Sep-25-19 06:22PM  
06:18PM  
07:00AM  
Sep-18-19 10:33AM  
08:42AM  
07:00AM  
Sep-16-19 10:29AM  
Sep-13-19 10:30AM  
08:42AM  
Sep-12-19 08:35AM  
Sep-11-19 11:37AM  
Sep-10-19 09:01AM  
07:59AM  
Sep-09-19 03:51PM  
Sep-03-19 11:00AM  
Aug-31-19 09:32AM  
Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Selincro, an orally administered drug for the treatment of alcohol dependence in Europe. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, the company develops Inbrija for the treatment of OFF periods in Parkinson's disease and ARCUS product for the treatment of acute migraine. Further, it develops rHIgM22, which has completed Phase I clinical trial for the treatment of MS; and Cimaglermin alfa that is in Phase Ib clinical trial for heart failure patients. The company has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. Acorda Therapeutics, Inc. was founded in 1995 and is headquartered in Ardsley, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Wasman JanePresident, Intl and GCDec 02Sale1.602,2273,553117,420Dec 04 07:53 AM
Sabella Lauren MChief Commercial OfficerDec 02Sale1.601,5132,42112,624Dec 04 07:51 AM
LAWRENCE DAVIDChief, Bus. Ops & PAODec 02Sale1.601,1761,88012,961Dec 04 07:49 AM
COHEN RONPresident and CEODec 02Sale1.604,6997,505607,287Dec 04 07:47 AM
affiliate | advertise | contact | privacy | help
Do not sell my personal information

Quotes delayed 15 minutes for NASDAQ, and 20 minutes for NYSE and AMEX.
Copyright © 2007-2020 FINVIZ.com. All Rights Reserved.